Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

• Genmab A/S is positioned for a pivotal fourth quarter with three Phase III readouts planned for late-stage oncology programs, including EPKINLY in frontline diffuse large B-cell lymphoma, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line metastatic head and neck cancer, which the company views as potential first-in-class opportunities that could significantly expand its market reach.
• The stock recently hit a new 52-week high, trading at $35.67 as of September 30, 2026, reflecting strong momentum and investor confidence following a series of positive analyst upgrades and a consensus rating of Moderate Buy with a target price of $39.50, suggesting further upside potential.
• Genmab A/S demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $0.54, which beat analysts' consensus estimates of $0.37 by $0.17, and revenue of $1.16 billion, exceeding the consensus estimate of $1.12 billion, indicating robust operational execution and demand for its antibody-based medicines.
• Analysts have recently raised their earnings estimates for Genmab A/S, with HC Wainwright increasing its full-year 2026 earnings per share forecast to $1.48 from a previous estimate of $1.21, and also raising its Q3 2026 estimate to $0.49 from $0.37, signaling growing confidence in the company's ability to deliver on its growth targets.
• Short interest in Genmab A/S has decreased significantly over the past few months, with the number of shares shorted dropping from 11,896,539 in November 2025 to 4,920,530 as of September 2026, suggesting that investors are increasingly confident in the stock's future performance and are less likely to bet against it.